Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC)

BACKGROUND: Clinical guidelines recommend at least 3-months low molecular weight heparin (LMWH) treatment for established venous thromboembolism (VTE) in cancer patients. However, no study has analyzed the impact of 3–6 months of LMWH therapy on quality-of-life (QoL) in cancer patients. RESULTS: Amo...

Descripción completa

Detalles Bibliográficos
Autores principales: Farge, Dominique, Cajfinger, Francis, Falvo, Nicolas, Berremili, Toufek, Couturaud, Francis, Bensaoula, Okba, Védrine, Lionel, Bensalha, Hocine, Bonnet, Isabelle, Péré-Vergé, Denis, Coudurier, Marie, Li, Veronique, Rafii, Hanadi, Benzidia, Ilham, Connors, Jean M., Resche-Rigon, Matthieu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007467/
https://www.ncbi.nlm.nih.gov/pubmed/29930745
http://dx.doi.org/10.18632/oncotarget.25454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007467/
https://www.ncbi.nlm.nih.gov/pubmed/29930745
http://dx.doi.org/10.18632/oncotarget.25454

Ejemplares similares